Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where V. Sblendorio is active.

Publication


Featured researches published by V. Sblendorio.


Pharmacological Research | 2011

Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice

Anna Cozzoli; Beatrice Nico; V. Sblendorio; Roberta Francesca Capogrosso; Maria Maddalena Dinardo; Vito Longo; Sara Gagliardi; Monica Montagnani; Annamaria De Luca

Graphical abstract Highlights ► An early treatment with enalapril was performed in exercised mdx mice. ► In vivo, enalapril increased mouse fore limb strength dose-dependently. ► Ex vivo, enalapril reduced muscular markers of oxidative stress and inflammation. ► Results corroborate an early role of angiotensin II in muscular dystrophy. ► Pre-clinical evidences of therapeutic interest of ACE inhibitors for therapy of DMD.


Neuropathology and Applied Neurobiology | 2011

Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy

Anna Cozzoli; Jean-François Rolland; Roberta Francesca Capogrosso; V. Sblendorio; Vito Longo; Simonetta Simonetti; Beatrice Nico; A. De Luca

A. Cozzoli, J.‐F. Rolland, R. F. Capogrosso, V. T. Sblendorio, V. Longo, S. Simonetti, B. Nico and A. De Luca (2011) Neuropathology and Applied Neurobiology37, 243–256
Evaluation of potential synergistic action of a combined treatment with alpha‐methyl‐prednisolone and taurine on the mdx mouse model of Duchene muscular dystrophy


Pharmacological Research | 2016

Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone

Roberta Francesca Capogrosso; Anna Cozzoli; Paola Mantuano; Giulia Maria Camerino; Ada Maria Massari; V. Sblendorio; Michela De Bellis; Roberto Tamma; Arcangela Giustino; Beatrice Nico; Monica Montagnani; Annamaria De Luca

Antioxidants have a great potential as adjuvant therapeutics in patients with Duchenne muscular dystrophy, although systematic comparisons at pre-clinical level are limited. The present study is a head-to-head assessment, in the exercised mdx mouse model of DMD, of natural compounds, resveratrol and apocynin, and of the amino acid taurine, in comparison with the gold standard α-methyl prednisolone (PDN). The rationale was to target the overproduction of reactive oxygen species (ROS) via disease-related pathways that are worsened by mechanical-metabolic impairment such as inflammation and over-activity of NADPH oxidase (NOX) (taurine and apocynin, respectively) or the failing ROS detoxification mechanisms via sirtuin-1 (SIRT1)-peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) (resveratrol). Resveratrol (100mg/kg i.p. 5days/week), apocynin (38mg/kg/day per os), taurine (1g/kg/day per os), and PDN (1mg/kg i.p., 5days/week) were administered for 4-5 weeks to mdx mice in parallel with a standard protocol of treadmill exercise and the outcome was evaluated with a multidisciplinary approach in vivo and ex vivo on pathology-related end-points and biomarkers of oxidative stress. Resveratrol≥taurine>apocynin enhanced in vivo mouse force similarly to PDN. All the compounds reduced the production of superoxide anion, assessed by dihydroethidium staining, with apocynin being as effective as PDN, and ameliorated electrophysiological biomarkers of oxidative stress. Resveratrol also significantly reduced plasma levels of creatine kinase and lactate dehydrogenase. Force of isolated muscles was little ameliorated. However, the three compounds improved histopathology of gastrocnemius muscle more than PDN. Taurine>apocynin>PDN significantly decreased activated NF-kB positive myofibers. Thus, compounds targeting NOX-ROS or SIRT1/PGC-1α pathways differently modulate clinically relevant DMD-related endpoints according to their mechanism of action. With the caution needed in translational research, the results show that the parallel assessment can help the identification of best adjuvant therapies.


PLOS ONE | 2013

Effects of Pleiotrophin Overexpression on Mouse Skeletal Muscles in Normal Loading and in Actual and Simulated Microgravity

Giulia Maria Camerino; Sabata Pierno; Antonella Liantonio; Michela De Bellis; Maria Cannone; V. Sblendorio; Elena Conte; Antonietta Mele; Domenico Tricarico; Sara Tavella; Alessandra Ruggiu; Ranieri Cancedda; Yoshinobu Ohira; Daniela Danieli-Betto; Stefano Ciciliot; Elena Germinario; Dorianna Sandonà; Romeo Betto; Diana Conte Camerino; Jean François Desaphy

Pleiotrophin (PTN) is a widespread cytokine involved in bone formation, neurite outgrowth, and angiogenesis. In skeletal muscle, PTN is upregulated during myogenesis, post-synaptic induction, and regeneration after crushing, but little is known regarding its effects on muscle function. Here, we describe the effects of PTN on the slow-twitch soleus and fast-twitch extensor digitorum longus (EDL) muscles in mice over-expressing PTN under the control of a bone promoter. The mice were maintained in normal loading or disuse condition, induced by hindlimb unloading (HU) for 14 days. Effects of exposition to near-zero gravity during a 3-months spaceflight (SF) into the Mice Drawer System are also reported. In normal loading, PTN overexpression had no effect on muscle fiber cross-sectional area, but shifted soleus muscle toward a slower phenotype, as shown by an increased number of oxidative type 1 fibers, and increased gene expression of cytochrome c oxidase subunit IV and citrate synthase. The cytokine increased soleus and EDL capillary-to-fiber ratio. PTN overexpression did not prevent soleus muscle atrophy, slow-to-fast transition, and capillary regression induced by SF and HU. Nevertheless, PTN exerted various effects on sarcolemma ion channel expression/function and resting cytosolic Ca2+ concentration in soleus and EDL muscles, in normal loading and after HU. In conclusion, the results show very similar effects of HU and SF on mouse soleus muscle, including activation of specific gene programs. The EDL muscle is able to counterbalance this latter, probably by activating compensatory mechanisms. The numerous effects of PTN on muscle gene expression and functional parameters demonstrate the sensitivity of muscle fibers to the cytokine. Although little benefit was found in HU muscle disuse, PTN may emerge useful in various muscle diseases, because it exerts synergetic actions on muscle fibers and vessels, which could enforce oxidative metabolism and ameliorate muscle performance.


Endocrinology | 2013

Growth Hormone Secretagogues Exert Differential Effects on Skeletal Muscle Calcium Homeostasis in Male Rats Depending on the Peptidyl/Nonpeptidyl Structure

Antonella Liantonio; Gianluca Gramegna; Giuseppe Carbonara; V. Sblendorio; Sabata Pierno; Bodvaël Fraysse; Viviana Giannuzzi; Laura Rizzi; Antonio Torsello; Diana Conte Camerino

The orexigenic and anabolic effects induced by ghrelin and the synthetic GH secretagogues (GHSs) are thought to positively contribute to therapeutic approaches and the adjunct treatment of a number of diseases associated with muscle wasting such as cachexia and sarcopenia. However, many questions about the potential utility and safety of GHSs in both therapy and skeletal muscle function remain unanswered. By using fura-2 cytofluorimetric technique, we determined the acute effects of ghrelin, as well as of peptidyl and nonpeptidyl synthetic GHSs on calcium homeostasis, a critical biomarker of muscle function, in isolated tendon-to-tendon male rat skeletal muscle fibers. The synthetic nonpeptidyl GHSs, but not peptidyl ghrelin and hexarelin, were able to significantly increase resting cytosolic calcium [Ca²⁺]i. The nonpeptidyl GHS-induced [Ca²⁺]i increase was independent of GHS-receptor 1a but was antagonized by both thapsigargin/caffeine and cyclosporine A, indicating the involvement of the sarcoplasmic reticulum and mitochondria. Evaluation of the effects of a pseudopeptidyl GHS and a nonpeptidyl antagonist of the GHS-receptor 1a together with a drug-modeling study suggest the conclusion that the lipophilic nonpeptidyl structure of the tested compounds is the key chemical feature crucial for the GHS-induced calcium alterations in the skeletal muscle. Thus, synthetic GHSs can have different effects on skeletal muscle fibers depending on their molecular structures. The calcium homeostasis dysregulation specifically induced by the nonpeptidyl GHSs used in this study could potentially counteract the beneficial effects associated with these drugs in the treatment of muscle wasting of cachexia- or other age-related disorders.


Neuromuscular Disorders | 2011

P4.26 Toward the identification of druggable pathways involved in disease-related fatigue in Duchenne muscular dystrophy: In vivo and ex vivo studies in dystrophic mdx mice

Roberta Francesca Capogrosso; Anna Cozzoli; V. Sblendorio; Giulia Maria Camerino; Robert W. Grange; A. De Luca

Toward the identification of druggable pathways involved in disease-related fatigue in Duchenne muscular dystrophy: In vivo and ex vivo studies in dystrophic mdx mice R.F. Capogrosso , A. Cozzoli , V. Sblendorio , G.M. Camerino , R.W. Grange , A. De Luca a a University of Bari, Department Pharmaco-Biology, Bari, Italy; b Virginia Tech, Department of Human Nutrition, Food and Exercise, Blacksburg, VA, United States


Neuromuscular Disorders | 2012

T.P.1 Parallel effects of α-methyl-prednisolone on skeletal muscle and brain of mdx mice: Identification of a novel mechanism of action

Beatrice Nico; Roberto Tamma; Tiziana Annese; Roberta Francesca Capogrosso; V. Sblendorio; Simona Ruggieri; Anna Cozzoli; Domenico Ribatti; A. De Luca


Neuromuscular Disorders | 2011

P4.45 Evaluation of the dual action of new derivatives of mexiletine as use-dependent sodium channel blockers and antioxidant: potential therapeutic application in neuromuscular disorders

M. De Bellis; V. Sblendorio; Alessia Carocci; Maria Maddalena Cavalluzzi; Giovanni Lentini; Carlo Franchini; A. De Luca; D. Conte Camerino


Neuromuscular Disorders | 2011

P4.16 Evaluation of potential efficacy of GLPG0492, a novel selective androgen receptor modulator, in the exercised-mdx mouse model: Comparison with α -methyl prednisolone and nandrolone

Anna Cozzoli; Roberta Francesca Capogrosso; V. Sblendorio; Catherine Jagerschmidt; Florence Namour; A. De Luca


Neuromuscular Disorders | 2011

P4.25 Cyclic nucleotide signalling pathways as a potential druggable target for enhancing regeneration potential in dystrophic skeletal muscle

V. Sblendorio; R.A. Watson; S. Woodhouse; J.M. Pell; A. De Luca

Collaboration


Dive into the V. Sblendorio's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge